Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.40 |
| ▸ | CLK1 | P49759 | 4/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19140129 | 0.85 | DYRK1A (0.52) | ALDH1A1HSD17B10DYRK1ACLK4CLK1 | |
| SCHEMBL27362369 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HSD17B10RIPK1RIPK3DYRK1A | |
| SCHEMBL1419323 | 0.81 | CYP2A6 (0.47) | ALDH1A1HSD17B10DYRK1ACLK4CLK1 | |
| SCHEMBL7218395 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HSD17B10RIPK1RIPK3DYRK1A | |
| SCHEMBL16693063 | 0.77 | ALDH1A1 (0.41) | ALDH1A1HSD17B10DYRK1ACLK4CLK1 | |
| SCHEMBL8039455 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HSD17B10RIPK1RIPK3ESR1 | |
| SCHEMBL8039453 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HSD17B10RIPK1RIPK3ESR1 | |
| SCHEMBL1850868 | 0.75 | NFE2L2 (0.44) | ALDH1A1HSD17B10RIPK1RIPK3DYRK1A | |
| SCHEMBL1850866 | 0.75 | NFE2L2 (0.44) | ALDH1A1HSD17B10RIPK1RIPK3DYRK1A | |
| Benzo[D]Thiazole SCHEMBL27574416 | 0.74 | ALDH1A1 (0.68) | ALDH1A1HSD17B10RIPK1RIPK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4583865-A1 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | Mydecine Innovations Group Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240400526-A9 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | MYDECINE INNOVATIONS GROUP INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240092747-A1 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | Altrartis Therapeutics Inc. | 2024-03-21 | — | — | US | disclosed |
| WO-2024054279-A1 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| EP-3247397-B1 | METAL-GLYCOPROTEIN COMPLEXES AND THEIR USE AS CHEMOTHERAPEUTIC COMPOUNDS | THERALASE TECH INC (CA) | 2021-05-19 | — | — | EP | disclosed |
| EP-3633380-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | disclosed |
| WO-2017090756-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | SLC6A3, SLC6A2, HTR2C | ALDH1A1 1951/4885HSD17B10 1783/4885RIPK1 2381/4885 |
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | KDM1B, KDM1A, DOT1L | ALDH1A1 538/4885HSD17B10 2827/4885RIPK1 1704/4885 |
| US-20240400526-A9 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | HTR3B, HTR3C, HTR3E | ALDH1A1 1860/4885HSD17B10 2297/4885RIPK1 3784/4885 |
| US-20240092747-A1 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | HTR3B, HTR3C, HTR3E | ALDH1A1 1860/4885HSD17B10 2297/4885RIPK1 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.